meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
1
mCRC - 2nd line (L2)
3
endometrial cancer
1
esophageal cancer (EC)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenvatinib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs taxanes
vs paclitaxel
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
endometrial cancer
endometrial cancer
versus paclitaxel
pembrolizumab plus lenvatinib vs. paclitaxel
1
certainty unassessable
-35%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open